NCT04081350

A Study of LY3471851 in Participants With Eczema

Completed Phase 1 Last updated 20 February 2024

What this trial tests

Phase 1 trial testing LY3471851 in Dermatitis, Atopic in 48 participants. Completed in 24 June 2022.

Timeline

4 December 2019

Primary endpoint
24 June 2022

24 June 2022

Quick facts

Lead sponsor	Nektar Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	48
Start date	4 December 2019
Primary completion	24 June 2022
Estimated completion	24 June 2022
Sites	20 locations across United States

Drugs / interventions tested

• LY3471851 — full drug profile →
• Placebo

Conditions studied

• Dermatitis, Atopic — all drugs for Dermatitis, Atopic →

Sponsor

Nektar Therapeutics — full company profile →

Who can join

Adults 18 to 70, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
   Bieber T. · · 2022 · cited 421× · PMID 34417579 · DOI 10.1038/s41573-021-00266-6
2. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
   Raeber ME, Sahin D, Karakus U, Boyman O. · · 2023 · cited 139× · PMID 37004361 · DOI 10.1016/j.ebiom.2023.104539
3. IL-2-based approaches to Treg enhancement.
   Harris F, Berdugo YA, Tree T. · · 2023 · cited 81× · PMID 36399073 · DOI 10.1093/cei/uxac105
4. Emerging Therapeutics for Immune Tolerance: Tolerogenic Vaccines, T cell Therapy, and IL-2 Therapy.
   Moorman CD, Sohn SJ, Phee H. · · 2021 · cited 77× · PMID 33854514 · DOI 10.3389/fimmu.2021.657768
5. "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity".
   Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM. · · 2023 · cited 61× · PMID 37741949 · DOI 10.1038/s41435-023-00221-y
6. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.
   Dixit N, Fanton C, Langowski JL, Kirksey Y, et al · · 2021 · cited 45× · PMID 34041473 · DOI 10.1016/j.jtauto.2021.100103
7. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
   Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, et al · · 2024 · cited 19× · PMID 39455575 · DOI 10.1038/s41467-024-53384-1
8. Tissue-specific roles of regulatory T cells: mechanisms of suppression and beyond along with emerging therapeutic insights in autoimmune indications.
   Jugder BE, Park E, Du L, Jawale C, et al · · 2025 · cited 3× · PMID 40933988 · DOI 10.3389/fimmu.2025.1650451